We have previously shown that the expression of miR-221 was associated with higher risk of metastasis in advanced breast cancers [10] and miR-221 was considered to be a prognostic marker for distinguishing subgroups particularly in advanced (lymph node-positive and HER2-positive) breast cancers [10]. This evidence concerns the gene ERBB2 and breast cancer.